1-12 of 12
Keywords: antibiotics
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Articles
Emerg Top Life Sci (2024) 8 (1): 37–43.
Published: 17 November 2023
...Calum M. Webster; Mark Shepherd It is well-known that antibiotics target energy-consuming processes and a significant body of research now supports the conclusion that the metabolic state of bacteria can have a profound impact upon the efficacy of antibiotics. Several articles implicate bacterial...
Articles
Emerg Top Life Sci (2021) 5 (5): 637–641.
Published: 01 November 2021
...Anne M. L. Barnard; James A. Cass Interest in phage-based therapeutics is increasing, at least in part due to the need for new treatment options for infections caused by antibiotic-resistant bacteria. It is possible to use wild-type (WT) phages to treat bacterial infections, but it is also possible...
Articles
Emerg Top Life Sci (2021) 5 (5): 629–635.
Published: 24 May 2021
... Society of Biology 2021 antibiotics cysteamine cystic fibrosis infection innate immunity vanin-1 Cysteamine is the simplest stable aminothiol and has been a molecule of therapeutic interest for scientists for decades. As the stable cysteamine bitartrate salt, it has been safely...
Articles
Articles
Emerg Top Life Sci (2020) 4 (6): 567–580.
Published: 03 December 2020
...Joanna Shepherd The global challenge of antimicrobial resistance is of increasing concern, and alternatives to currently used antibiotics or methods to improve their stewardship are sought worldwide. Microbial biofilms, complex 3D communities of bacteria and/or fungi, are difficult to treat...
Articles
Emerg Top Life Sci (2020) 4 (6): 555–566.
Published: 01 December 2020
...Ioanna Mela; Clemens F. Kaminski Antibiotic resistance has become one of the greatest challenges for modern medicine, and new approaches for the treatment of bacterial infections are urgently needed to avoid widespread vulnerability again to infections that have so far been easily treatable...
Articles
Emerg Top Life Sci (2017) 1 (1): 93–103.
Published: 21 April 2017
...Daniel Walker; Dwayne R. Roach; Laurent Debarbieux For a century, bacterial viruses called bacteriophages have been exploited as natural antibacterial agents. However, their medicinal potential has not yet been exploited due to readily available and effective antibiotics. After years of extensive...
Articles
Emerg Top Life Sci (2017) 1 (1): 105–116.
Published: 21 April 2017
...Daniel Walker; Shawna McCallin; Harald Brüssow Phage therapy is currently discussed as an alternative or adjunct to antibiotics whose activity is increasingly compromised by the emergence of antibiotic-resistant bacterial pathogens. The idea to use lytic bacterial viruses as antimicrobial agents...
Articles
Emerg Top Life Sci (2017) 1 (1): 65–74.
Published: 21 April 2017
...Daniel Walker; Hannah M. Behrens; Anne Six; Daniel Walker; Colin Kleanthous The growing incidence of antibiotic-resistant Gram-negative bacterial infections poses a serious threat to public health. Molecules that have yet to be exploited as antibiotics are potent protein toxins called bacteriocins...
Articles
Emerg Top Life Sci (2017) 1 (1): 23–30.
Published: 04 April 2017
... challenges. Since QS controls the ability of many pathogenic bacteria to cause disease, it is an attractive target for novel antibacterial agents that control infection through inhibition of virulence and by rendering biofilms more susceptible to conventional antibiotics and host clearance pathways. QS...
Articles
Emerg Top Life Sci (2017) 1 (1): 85–92.
Published: 04 April 2017
...Daniel Walker; Peter W. Taylor The relentless increase in antibiotic resistance among all major groups of bacterial pathogens shows no sign of abating. The situation is exacerbated by a marked decline in the number of new antibiotics entering the marketplace. It is essential that new ways to treat...
Articles
Emerg Top Life Sci (2017) 1 (1): 1–12.
Published: 04 April 2017
... people a year worldwide by 2050. Almost all the antibiotics currently in clinical use are derived from the secondary metabolites of a group of filamentous soil bacteria called actinomycetes, most notably in the genus Streptomyces . Unfortunately, the discovery of these strains and their natural products...